Eaton Vance Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Eaton Vance Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-38	Closed	-$2K	–	2816
2021 Q4	$2K	Hold	38	–	–	﹤0.01%	2749
2021 Q3	$3K	Hold	38	–	–	﹤0.01%	1903
2021 Q2	$4K	Sell	38 -37	-49%	-$4.09K	﹤0.01%	2671
2021 Q1	$11K	Buy	+75	New	+$13.6K	﹤0.01%	2346

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Eaton Vance Management's NBSE Position: Q1 2022 in Review

Eaton Vance Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2022, closing a stake of 38 shares — an estimated $2K sold.

Eaton Vance Management first reported a position in NBSE in Q1 2021 and held it in 4 quarters. The position peaked at $11K in Q1 2021. 45 funds tracked by Wall St. Rank hold NBSE as of Q1 2022.

Eaton Vance Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 38 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $2K.
Eaton Vance Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Eaton Vance Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $11K in Q1 2021.
45 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.